Despite just one in seven of the public actually knowing what the current target in A&E is, although it has been used for 15 years.
News
LEO Pharma inks novel compounds deal with Ubiquigent
The companies initially entered an agreement in 2018 as part of LEO Pharma Open Innovation.
UK to be ‘transformed’ into radiotherapy research hub
The drive is supported by an additional £56 million funding from Cancer Research UK.
First patient dosed with Chiesi’s Holoclar
In 2017, NICE recommended Holoclar as an option for adults with moderate-to-severe LSCD after eye burns
PRAC cautions use of Lemtrada, Xeljanz in latest meeting
Pfizer’s Xeljanz could potentially increase the risk of blood clots.
Cosentyx ‘narrowly’ misses superiority VS Humira
AbbVie’s blockbuster Humira still holds the crown for being the world’s best selling drug.
‘Impressive’ results for Trikafta in cystic fibrosis
The results represent a “historic” moment in cystic fibrosis care.
GSK boosts forecast again on back of Shingrix sales
The pharma giant reported sales of £9.4 billion for the third quarter, with HIV drug sales also supporting profits.
Vumerity nabs FDA approval for MS
Biogen is set to pay Alkermes $150 million in connection with the approval.
Less painkillers being used during childbirth, report finds
The findings also show that deliveries for women under 20 have more than halved in a decade.
Dupixent scores another EU extension
The decision marks the first biologic approved in the European Union for severe chronic rhinosinusitis.
Categories developed for the 2020 International Clinical Researcher of the Year
The categories for the 2020 competition have been further developed to offer an even greater experience for entrants.
‘Incubator’ launched to support nurses to become research leaders
The project will help to accelerate and support the development of nurses and midwives looking to develop a career leading research.
MorphoSys, Novartis, Galapagos abandon experimental MOR106
The decision was based on a “low probability to meet main goal of study.”
AZ divests rights to Seroquel in Europe, Russia
The decision comes as both drugs, used primarily to treat schizophrenia and bipolar disorder, have lost their compound patent protection in the areas.
